SLC5A2 and heart failure: The low rate of SGLT2 inhibitor use among patients with HFrEF was consistent with recent evidence from an outpatient heart failure registry.29 In the commercially insured population in the present study, there were racial/ethnic, gender, and socioeconomic inequities in receipt of SGLT2 inhibitor therapy.